Loading data for LNSR — first visit, this takes a few seconds.
LENSAR, Inc.
8.31 -0.29 (-3.37%)
7.08 +0.00%
- Capitalización de mercado
- $86.98M
- Volumen
- 68.9K
- Próxima fecha de resultados
- Nov 12, 2026
LENSAR, Inc. (LNSR): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $16.50M | n/a | +18.37% |
| EPS | $0.10 | +$0.37 | +200.00% |
Métricas
- Precio de compra
- 6.19
- Ingresos (TTM)
- 60.3M
- Beneficio neto (TTM)
- 14.7M
- 0.97
- 0.2
- 35.4
- -9.97
- P/B (TTM)
- 5.83
- P/S (TTM)
- 1.44
- Fecha de resultados
- Nov 12, 2026
- Precio de venta
- 10.68
- Volumen
- 68,924
- Volumen medio (20D)
- 126,873
- Abierto
- 8.54
- Anterior Cerrar
- 8.60
- Rango del día
- 8.25 - 8.60
- Rango de 52 semanas
- 4.95 - 12.94
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de LENSAR, Inc.
Ver perfil →LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Industria Medical Devices
Sector Healthcare
IPO Fecha Oct 2, 2020
Empleados 150
Bolsa de Valores NasdaqCM
Símbolo bursátil LNSR
Sitio web https://www.lensar.com